Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.85 EUR
−37.55 M EUR
442.13 K EUR
59.78 M
About Cardiff Oncology, Inc.
Sector
Industry
CEO
Mark Erlander
Website
Headquarters
San Diego
Founded
1999
FIGI
BBG000QX2MR8
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where XE7C is featured.
Frequently Asked Questions
The current price of XE7C is 3.73 EUR — it has decreased by −4.06% in the past 24 hours. Watch CARDIFF ONCOLOGY INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CARDIFF ONCOLOGY INC stocks are traded under the ticker XE7C.
XE7C stock has fallen by −15.25% compared to the previous week, the month change is a 16.67% rise, over the last year CARDIFF ONCOLOGY INC has showed a 119.41% increase.
We've gathered analysts' opinions on CARDIFF ONCOLOGY INC future price: according to them, XE7C price has a max estimate of 19.24 EUR and a min estimate of 9.62 EUR. Watch XE7C chart and read a more detailed CARDIFF ONCOLOGY INC stock forecast: see what analysts think of CARDIFF ONCOLOGY INC and suggest that you do with its stocks.
XE7C reached its all-time high on Dec 1, 2020 with the price of 22.51 EUR, and its all-time low was 0.70 EUR and was reached on Mar 19, 2020. View more price dynamics on XE7C chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XE7C stock is 5.63% volatile and has beta coefficient of 0.98. Track CARDIFF ONCOLOGY INC stock price on the chart and check out the list of the most volatile stocks — is CARDIFF ONCOLOGY INC there?
Today CARDIFF ONCOLOGY INC has the market capitalization of 259.74 M, it has decreased by −9.61% over the last week.
Yes, you can track CARDIFF ONCOLOGY INC financials in yearly and quarterly reports right on TradingView.
CARDIFF ONCOLOGY INC is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
XE7C earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.24 EUR resulting in a 10.70% surprise. The estimated earnings for the next quarter are −0.19 EUR per share. See more details about CARDIFF ONCOLOGY INC earnings.
CARDIFF ONCOLOGY INC revenue for the last quarter amounts to 147.79 K EUR, despite the estimated figure of 96.60 K EUR. In the next quarter, revenue is expected to reach 67.32 K EUR.
XE7C net income for the last quarter is −10.65 M EUR, while the quarter before that showed −11.00 M EUR of net income which accounts for 3.17% change. Track more CARDIFF ONCOLOGY INC financial stats to get the full picture.
No, XE7C doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 28, 2025, the company has 32.00 employees. See our rating of the largest employees — is CARDIFF ONCOLOGY INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CARDIFF ONCOLOGY INC EBITDA is −41.31 M EUR, and current EBITDA margin is −9.22 K%. See more stats in CARDIFF ONCOLOGY INC financial statements.
Like other stocks, XE7C shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CARDIFF ONCOLOGY INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CARDIFF ONCOLOGY INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CARDIFF ONCOLOGY INC stock shows the buy signal. See more of CARDIFF ONCOLOGY INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.